AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 24998644
Drug: Vaccine-induced inflammation
RxNorm normalized name: Inflammation OTC Bruise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine-induced inflammation (typhoid vaccination)
Trial: 8840384
Drug: Single-ingredient supplements
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-ingredient supplements
Trial: 1427586
Drug: Omeprazole 30
RxNorm normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Omeprazole 30 mg/day
Trial: 12702130
Drug: HIV‐1 rgp160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIV‐1 rgp160 vaccine
Trial: 12702130
Drug: Tetanus vaccine
RxNorm normalized name: Tetanus vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tetanus vaccine (Control group)
Trial: 10233027
Drug: Estradiol-17beta (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estradiol-17beta (1 mg micronized steroid twice daily orally)
Trial: 28024819
Drug: Lava C.O.S.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lava C.O.S. CAD software and centralized CAM (group L)
Trial: 12229073
Drug: Tracking procedures
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tracking procedures used in Project Towards No Drug Abuse (Project TND)
Trial: 31238912
Drug: Reduced-dosage ketoprofen
RxNorm normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reduced-dosage ketoprofen (0.5 mg/kg SC once; 0.25 mg/kg PO daily)
Trial: 31238912
Drug: Reduced-dosage ketoprofen
RxNorm normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reduced-dosage ketoprofen (0.5 mg/kg SC once; 0.25 mg/kg PO daily) + tramadol (5 mg/kg/day PO)
Trial: 31238912
Drug: Standard-dosage ketoprofen
RxNorm normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard-dosage ketoprofen (2 mg/kg SC, then 1 mg/kg PO daily)
Trial: 21606427
Drug: Fluorouracil (225
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluorouracil (225 mg/m(2)/d) plus pelvic radiation (50.4 Gy in 28 daily fractions)
Trial: 21606427
Drug: Fluorouracil (225
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluorouracil (225 mg/m(2)/d) plus pelvic radiation (50.4 Gy in 28 daily fractions) and oxaliplatin (60 mg/m(2) weekly × 6)
Trial: 19138610
Drug: Superior joint
RxNorm normalized name: Astaxanthin/Hyaluronic Acid/Krill Oil Oral Capsule, Liquid Filled [MEGARED SUPERIOR JOINT CARE]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Superior joint space injections of sodium hyaluronate
Trial: 19138610
Drug: Inferior joint
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inferior joint space injections of sodium hyaluronate
Trial: 15582012
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg of dried ethanolic extract of guarana (approx 12% caffeine)
Trial: 15582012
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg of Panax ginseng (G115)
Trial: 15582012
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 75 mg guarana and 200 mg Panax ginseng
Trial: 11328420
Drug: Postoperative intravesical
RxNorm normalized name: Valrubicin Intravesical Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative intravesical instillation of mitomycin C (20 mg) and cytosine arabinoside (200 mg) 28 times over 2 years
Trial: 12188443
Drug: Allopurinol 300
RxNorm normalized name: allopurinol 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allopurinol 300 mg/day
Trial: 12188443
Drug: Benzbromarone 100
RxNorm normalized name: benzbromarone 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benzbromarone 100 mg/day
Trial: 9849314
Drug: Allopurinol 450
RxNorm normalized name: Allopurinol
DrugBank: Allopurinol (DB00437)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Allopurinol 450 to 600 mg/day
Trial: 9849314
Drug: Benzbromarone (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benzbromarone (mean final dose 76 mg/day)
Trial: 12883589
Drug: Ranitidine 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine 600 mg
Trial: 7986969
Drug: Ranitidine 1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine 1200 mg
Trial: 2722308
Drug: 3 x
RxNorm normalized name: Xenon (133 xe)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 x 450 mg 3‐sn‐polyenyl‐phosphatidylcholine (PPC)
Trial: 25332469
Drug: Calcium (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium (100 mg/test meal)
Trial: 25332469
Drug: Calcium (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium (200 mg/test meal)
Trial: 25332469
Drug: Ascorbic acid
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ascorbic acid (AA) at 42.5 mg/test meal
Trial: 25332469
Drug: Ascorbic acid
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ascorbic acid (AA) at 85 mg/test meal
Trial: 23895132
Drug: Kaempferol (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kaempferol (150 mg/kg)
Trial: 23895132
Drug: Kaempferol (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kaempferol (30 mg/kg)
Trial: 23895132
Drug: Fenofibrate (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenofibrate (12 mg/kg)
Trial: 18166838
Drug: Pemetrexed (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pemetrexed (500 mg/m2 once every 3 weeks)
Trial: 18166838
Drug: Docetaxel (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Docetaxel (75 mg/m2 once every 3 weeks)
Trial: 6256423
Drug: Theophylline (therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theophylline (therapeutic doses given intravenously and orally over 3 days)
Trial: 25712577
Drug: 400 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 μg of misoprostol (n = 30)
Trial: 25712577
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg of dinoprostone (n = 30)
Trial: 17414237
Drug: Nicotine replacement
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine replacement therapy (15‐mg patch, 4‐mg gum, and/or 10‐mg inhaler)
Trial: 12410126
Drug: Inhibitor of
RxNorm normalized name: Membrane inhibitor of reactive lysis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhibitor of specific tyrosine kinase
Trial: 9857531
Drug: Sera containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sera containing specific antibodies for Staphylococcus aureus and Escherichia coli obtained from immunized rabbits
Trial: 9857531
Drug: Autologous bacterial
RxNorm normalized name: Autologous cultured fibroblasts
DrugBank: Azficel-T (DB11051)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous bacterial strains incubated with asthmatic patients' sera collected after autovaccines treatment
Trial: 9857531
Drug: Anti-IgE antibodies
RxNorm normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Anti-IgE antibodies
Trial: 43650
Drug: Thoracic epidural
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thoracic epidural block followed by intravenous prenalterol administration prior to induction of general anaesthesia
Trial: 43650
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no specific treatment prior to general anaesthesia)
Trial: 29879249
Drug: Topical oxymetazoline
RxNorm normalized name: oxymetazoline Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical oxymetazoline cream 1.0%
Trial: 27007800
Drug: Gabapentin (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabapentin (600 mg preoperatively, one hour prior to surgery)
Trial: 22768902
Drug: Olibra™ fat
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olibra™ fat emulsion (2.1 g twice daily)
Trial: 22768902
Drug: Placebo (1.95
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (1.95 g milk fat, twice daily)
Trial: 19417772
Drug: Moderate-intensity programme
RxNorm normalized name: PUMP,LUTREPULSE PROGRAMMABLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate-intensity programme with physician meetings, physical activity prescriptions, group counselling and bicycles
Trial: 17495770
Drug: ProDisc-L (Synthes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ProDisc-L (Synthes Spine) lumbar total disc replacement
Trial: 7988250
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy with cyclophosphamide, doxorubicin, and cisplatin (CAP) - 400 mg/m2 of cyclophosphamide, 40 mg/m2 of doxorubicin, and 60 mg/m2 of cisplatin, administered in four courses at 3-week intervals starting 30 days post-surgery.
Trial: 2660374
Drug: Tablets with
RxNorm normalized name: Aconitum napellus/Evening Trumpetflower/Onion/Zinc Gluconate 6 X-6 X-6 X-2 X Sublingual Tablet [HYLAND'S COLD TABLETS WITH ZINC]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets with normal particle size
Trial: 2660374
Drug: Tablets with
RxNorm normalized name: Aconitum napellus/Evening Trumpetflower/Onion/Zinc Gluconate 6 X-6 X-6 X-2 X Sublingual Tablet [HYLAND'S COLD TABLETS WITH ZINC]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets with coarse particle size
Trial: 4600903
Drug: Idoxuridine 5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Idoxuridine 5% in 100% dimethyl sulphoxide (DMSO), applied four-hourly for four days
Trial: 4600903
Drug: Idoxuridine 25%,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Idoxuridine 25%, applied two-hourly
Trial: 31804851
Drug: Insulin Aspart
RxNorm normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Insulin Aspart Biosimilar SAR341402 (SAR‐Asp)
Trial: 31804851
Drug: Originator Insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Originator Insulin Aspart (NN‐Asp)
Trial: 23635731
Drug: Bazedoxifene 20
RxNorm normalized name: bazedoxifene 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bazedoxifene 20 mg and conjugated estrogens 0.45 mg
Trial: 23635731
Drug: Bazedoxifene 20
RxNorm normalized name: bazedoxifene 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bazedoxifene 20 mg and conjugated estrogens 0.625 mg
Trial: 23635731
Drug: Conjugated estrogens
RxNorm normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conjugated estrogens 0.45 mg and medroxyprogesterone acetate 1.5 mg
Trial: 16792584
Drug: Specific immunotherapy
RxNorm normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specific immunotherapy (SIT) for 3 years
Trial: 16120066
Drug: Indinavir pharmacokinetics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indinavir pharmacokinetics
Trial: 9110067
Drug: Oral ganciclovir
RxNorm normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral ganciclovir maintenance
Trial: 1937663
Drug: Unfiltered boiled
RxNorm normalized name: BOIL-EASE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unfiltered boiled coffee (caffeine content 860 mg/l)
Trial: 1937663
Drug: Boiled-and-filtered coffee
RxNorm normalized name: Coffee bean
DrugBank: Coffee bean (DB10525)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Boiled-and-filtered coffee (caffeine content 887 mg/l)
Trial: 22845421
Drug: Motivational interviewing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Motivational interviewing (MI) session before periodontal treatment
Trial: 19201327
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no enamel treatment)
Trial: 17484067
Drug: Naltrexone (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone (50 mg for 3 days)
Trial: 11799306
Drug: Rhubarb-sage cream
RxNorm normalized name: RHUBARB
DrugBank: Rhubarb (DB10651)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rhubarb-sage cream (23 mg/g rhubarb extract, 23 mg/g sage extract)
Trial: 11799306
Drug: Sage cream
RxNorm normalized name: ARTEMISIA ARGYI LEAF 0.38 g in 100 mL TOPICAL CREAM [GONGFUTOUTANG Head massage cream]
DrugBank: Sage (DB10982)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sage cream (23 mg/g sage extract)
Trial: 11799306
Drug: Zovirax cream
RxNorm normalized name: acyclovir Topical Cream [Zovirax]
DrugBank: Acyclovir (DB00787)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zovirax cream (50 mg/g aciclovir)
Trial: 11799306
Drug: Zovirax cream
RxNorm normalized name: acyclovir Topical Cream [Zovirax]
DrugBank: Acyclovir (DB00787)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zovirax cream
Trial: 11799306
Drug: Rhubarb-sage cream
RxNorm normalized name: RHUBARB
DrugBank: Rhubarb (DB10651)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rhubarb-sage cream
Trial: 7919069
Drug: Warfarin (INR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin (INR 2 - 3)
Trial: 28331003
Drug: Taselisib 3-16
RxNorm normalized name: Taselisib
DrugBank: Taselisib (DB12108)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taselisib 3-16 mg once-daily capsule
Trial: 28331003
Drug: Taselisib 12
RxNorm normalized name: Taselisib
DrugBank: Taselisib (DB12108)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taselisib 12 mg
Trial: 28331003
Drug: Taselisib (any
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taselisib (any dose)
Trial: 23945571
Drug: IM gentamicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IM gentamicin OD and oral amoxicillin twice daily for 7 days
Trial: 23945571
Drug: IM penicillin
RxNorm normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IM penicillin and gentamicin OD for 2 days, followed by oral amoxicillin twice daily for 5 days
Trial: 23945571
Drug: 7 days
RxNorm normalized name: ZINGIBER OFFICINALE (GINGER) ROOT OIL 0.006 mg in 30 mg TOPICAL LIQUID [JAYSUING 7 Days Nail Fungus Treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7 days of once‐daily (OD) intramuscular (IM) procaine penicillin and gentamicin
Trial: 21685374
Drug: Imatinib 400
RxNorm normalized name: imatinib 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imatinib 400 mg daily plus Pegylated IFN-α2b 50 μg weekly
Trial: 21685374
Drug: Imatinib 400
RxNorm normalized name: imatinib 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imatinib 400 mg daily monotherapy
Trial: 18436182
Drug: Sublingual hyoscyamine
RxNorm normalized name: hyoscyamine Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual hyoscyamine spray (0.25 mg)
Trial: 16494628
Drug: Nandrolone decanoate
RxNorm normalized name: Nandrolone Decanoate
DrugBank: Nandrolone decanoate (DB08804)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nandrolone decanoate (150 mg)
Trial: 16494628
Drug: Testosterone (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Testosterone (250 mg)
Trial: 12931748
Drug: Topical antihistamine
RxNorm normalized name: Ahist Antihistamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical antihistamine (4 times daily)
Trial: 12931748
Drug: Topical lodoxamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical lodoxamide (4 times daily)
Trial: 12931748
Drug: Topical cyclosporine
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical cyclosporine 0.5% (4 times daily)
Trial: 12931748
Drug: Topical cyclosporine
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical cyclosporine compared to topical corticosteroids
Trial: 10980901
Drug: Standard doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard doses of ACE inhibitors
Trial: 10980901
Drug: Angiotensin II
RxNorm normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Angiotensin II type I receptor blockade (ARB)
Trial: 10980901
Drug: Higher-than-standard doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher-than-standard doses of ACE inhibitors
Trial: 9183781
Drug: Packy &
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Packy & Marlon (treatment group)
Trial: 25016274
Drug: Manual Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual Therapy (Maitland joint mobilization)
Trial: 25016274
Drug: Electrophysical Agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electrophysical Agents (TENS and cold pack)
Trial: 20719727
Drug: Atorvastatin 40
RxNorm normalized name: atorvastatin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 40 mg daily for at least 1 month preoperatively
Trial: 20719727
Drug: No atorvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No atorvastatin preoperatively
Trial: 12552338
Drug: Amino acid
RxNorm normalized name: Amino Acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amino acid infusion (lysine +/- arginine)
Trial: 8609343
Drug: Tumor necrosis
RxNorm normalized name: Tumor necrosis factor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tumor necrosis factor-alpha levels in patients in functional classes I to III (1.95 +/- 0.54, 2.63 +/- 0.48, 6.4 +/- 1.9 pg/ml)
Trial: 8609343
Drug: Interleukin-6 levels
RxNorm normalized name: interleukin-6
DrugBank: Human interleukin-6 (DB15060)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interleukin-6 levels in patients in functional classes I to III (3.3 +/- 0.55, 6.2 +/- 1.1, 5.22 +/- 0.9 pg/ml)
Trial: 18725484
Drug: Metoprolol (beta(1)-selective
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol (beta(1)-selective adrenergic blocker)
Trial: 8859726
Drug: recombinant interleukin‐2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: recombinant interleukin‐2 (rIL‐2) at doses of 3.0, 12.0, and 48.0 x 10(6) IU/m(2) i.v. three times weekly (TIW) and recombinant human IL‐4 (rHuIL‐4) at doses of 40, 120, and 400 mu g/m(2) s.c. TIW
Trial: 1517910
Drug: Cow milk-specific
RxNorm normalized name: Cow milk
DrugBank: Cow milk (DB10543)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cow milk-specific antibody responses
Trial: 1517910
Drug: IgE-specific antibody
RxNorm normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IgE-specific antibody concentrations and IgE/IgG-specific ratios for both milk proteins
Trial: 1517910
Drug: IgG1- and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IgG1- and IgG4-specific antibody to casein
Trial: 21864417
Drug: DHA-rich fish
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHA-rich fish oil (1 g/d)
Trial: 21864417
Drug: EPA-rich fish
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EPA-rich fish oil (1 g/d)
Trial: 17823963
Drug: 480 mg
RxNorm normalized name: magaldrate 480 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 480 mg caffeine
Trial: 17445520
Drug: Caffeine-free (placebo)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine-free (placebo) solution
Trial: 8936618
Drug: Gargling with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gargling with a remote foot pedal-operated gargling apparatus 3 times during daily work over a 3-month period
Trial: 26873871
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy of Exenatide and Metformin (5 μg Exenatide + 0.5 g MET twice daily for 4 weeks, then 10 μg Exenatide + 0.5 g MET twice daily for 24 weeks)
Trial: 20508383
Drug: Fasting plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fasting plasma glucose (FPG) value of 95-99 mg/dL
Trial: 20508383
Drug: Fasting plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fasting plasma glucose (FPG) value of 100-104 mg/dL
Trial: 20508383
Drug: Fasting plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fasting plasma glucose (FPG) value of 105-109 mg/dL
Trial: 20508383
Drug: Fasting plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fasting plasma glucose (FPG) value of 110-114 mg/dL
Trial: 20508383
Drug: Fasting plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fasting plasma glucose (FPG) value of 115-119 mg/dL
Trial: 20508383
Drug: Fasting plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fasting plasma glucose (FPG) value of 120-125 mg/dL
Trial: 20508383
Drug: Fasting plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fasting plasma glucose (FPG) value of 102 mg/dL
Trial: 18353592
Drug: 4-hydroxy-anethole trithione
RxNorm normalized name: anethole trithione
DrugBank: Anethole trithione (DB13853)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4-hydroxy-anethole trithione (ATX) tablets produced by different companies
Trial: 18353592
Drug: ATX tablets
RxNorm normalized name: ATX-01
DrugBank: ATX-01 (DB18141)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ATX tablets
Trial: 17117566
Drug: Acupuncture plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture plus western medicine (treatment group)
Trial: 17117566
Drug: Simple western
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simple western medicine (control group)
Trial: 12842239
Drug: No antiplatelet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antiplatelet agent treatment
Trial: 10923774
Drug: Ondansetron 24
RxNorm normalized name: ondansetron 24 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron 24 mg
Trial: 4032389
Drug: Lavage with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lavage with 800 ml of saline plus 2 gm of cefamandole nafate